Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14(ARF) Tumor Suppressor Genes

The adenovirus mutant ONYX-015 is in phase III clinical trials as a novel antitumor therapy. Its apparent efficacy is thought to be due to its ability to replicate selectively in tumor cells defective in the signaling pathway for p53. Recent data have shown that p14(ARF), a positive regulator of p53...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	J Virol
المؤلفون الرئيسيون:	Edwards, Sara J., Dix, Brett R., Myers, Colleen J., Dobson-Le, Deirdre, Huschtscha, Lily, Hibma, Merilyn, Royds, Janice, Braithwaite, Antony W.
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	American Society for Microbiology (ASM) 2002
الموضوعات:	Replication
الوصول للمادة أونلاين:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC136704/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12438574/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/JVI.76.24.12483-12490.2002
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!